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Abstract: This review aims to discuss the varied types of inhibitors of biotin-dependent carboxylases, with an emphasis
on the inhibitors of pyruvate carboxylase. Some of these inhibitors are physiologically relevant, in that they provide ways
of regulating the cellular activities of the enzymes e.g. aspartate and prohibitin inhibition of pyruvate carboxylase. Most
of the inhibitors that will be discussed have been used to probe various aspects of the structure and function of these
enzymes. They target particular parts of the structure e.g. avidin – biotin, FTP – ATP binding site, oxamate – pyruvate
binding site, phosphonoacetate – binding site of the putative carboxyphosphate intermediate.

Keywords: Pyruvate carboxylase, biotin-dependent enzyme, avidin, biotin, nucleotide inhibitors, acetyl coenzyme A, allosteric
inhibitors, chlorothricin.
INTRODUCTION
Pyruvate carboxylase (PC, EC 6.4.1.1), a regulatory
metabolic enzyme responsible for replenishing the intermediates of the TCA cycle and catalyzing the first committed
step in gluconeogenesis, is found in a wide variety of
organisms including bacteria, fungi, plants, invertebrates and
vertebrates [1]. Eukaryotic PC is generally located in the
mitochondria with the exception of yeast, where the two isoforms of PC (Pyc1 and Pyc2) are encoded by different genes,
and fungal PC, both of which are localized in the cytoplasm
[2].
Abnormalities in PC activity and regulation have been
associated with the occurrence of Type II diabetes [3] resulting in impaired-glucose tolerance and insulin insensitivity
[4]. In pre-diabetic patients, pancreatic islets compensate for
the escalating insulin-resistance by increasing glucosestimulated insulin secretion (GSIS) [3, 5]. Studies performed
by Jensen and co-workers [6] proposed that GSIS activity
was tightly correlated with the PC-catalyzed anaplerotic flux
through the TCA cycle and subsequent cycling of pyruvate
through the malate-pyruvate shuttle. Recently, the use of
small interfering RNA (si-RNA) to partially suppress PC
activity in INS-1 83/13-derived cell lines by Hasan et al. [7]
demonstrated that decreases in GSIS were directly proportional to decreases in PC activity. Furthermore, Liu et al. [8]
previously observed a 2-fold increase in in vivo PC -cell
activity and GSIS in obese, non-diabetic, insulin-resistant
Zucker fatty rats as compared to non-insulin resistant Zucker
lean rats. Inhibition of PC by the addition of phenylacetate
resulted in not only a marked decrease in PC activity, but
*Address correspondence to this author at the School of Biomedical,
Biomolecular and Chemical Sciences, University of Western Australia,
Crawley, WA6009, Australia; Tel: +61 8 6488 3329; Fax: +61 8 6488 1148;
E-mail: pattwood@cyllene.uwa.edu.au
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also a corresponding decrease in GSIS. The decreased PC
activity and expression observed in the islets of diabetic rats,
which are insulin resistant and show little GSIS [9, 10]
further suggests that PC plays an important role in both GSIS
and -cell adaptation to insulin resistance in fully functioning pancreatic cells. While the mechanism by which PC
activity regulates and enhances GSIS is not completely understood, it has been proposed by MacDonald [11] and others [12] that the metabolic cycling of pyruvate through PC
and the subsequent formation of anaplerotic by-products,
including NADPH, aids in modulating GSIS in pancreatic
islets.
Abnormally, high hepatic PC activity was initially
observed in diabetic rats [5, 9, 10]. Deterioration of the GSIS
pathway, due in part to chronic exposure to fatty acids,
decreases the ability of the -cells to secrete insulin, and
can lead to the development of Type II diabetes [5, 13].
Metabolic flux through hepatic PC is normally attenuated
by the insulin-signaling pathway [14], but is increased in
Type II diabetics resulting in raised hepatic glucose production [3, 13]. The metabolic abnormalities in the regulation
and activities of PC associated with Type II diabetes make
PC an attractive molecular target for the development of
new therapeutic agents for the treatment of this progressive
disease.
Fan and co-workers [15] have recently established a connection between PC activity and the “mitochondria dysfunction” observed in malignant lung cancer [16]. 13C isotopomer
analysis by NMR revealed direct evidence for increased
glycolytic activity in malignant tumor cells and further
demonstrated that both PC expression and activity, in vivo,
were activated in human lung cancer. Previously, a nearly
100-fold increase in PC’s anaplerotic activity was observed
in in vitro studies of breast cancer cells [17] and PC’s
gluconeogenic activity was found to be elevated in hepatic
2010 Bentham Open
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PCs is highly regulated by acetyl CoA, PC from some bacterial and fungi sources have no acetyl CoA dependence [1].

tumors in rats [18], demonstrating that increased PC activity
correlates with the uncontroled proliferation of tumor cells.
Therefore, the selective inhibition of PC activities in tumor
cells may prove to be a viable, alternative target for newly
emerging antiproliferative cancer treatments.

Similar to other biotin-dependent carboxylases, including
acetyl CoA carboxylase, propionyl CoA carboxylase and
methyl malonyl CoA carboxylase, PC catalyses the carboxylation of pyruvate in two distinct steps which occur at
discrete active sites (Fig. 1A). Biotin, which is covalently
attached to the -NH2 of a strictly conserved lysine residue
located at the C-terminal end of the BCCP, is carboxylated at
the N-1 position in the BC domain via the ATP-dependent
activation of bicarbonate and formation of a putative
carboxyphosphate intermediate [22]. Acting as a mobile
carboxyl carrier, carboxybiotin is then translocated from the
BC domain to a neighbouring CT domain where it is decarboxylated (Fig. 1B). Prior to carboxylation, the transfer of a
proton from pyruvate to biotin, facilitated by a strictly conserved Thr residue, is proposed to aid in the formation the
nucleophilic enol-pyruvate [23]. The carboxyl group is then
transferred to the nucleophilic substrate, forming oxaloacetate (Fig. 1B).

The connection between abnormal PC activity, Type II
diabetes and cancer substantiates the importance of understanding the structure, mechanism and inhibition of this
regulatory enzyme. The native structure of PC from most
sources is an ()4 tetramer, where the biotin carboxylase
(BC), carboxyl transferase (CT), biotin-carboxyl carrier protein (BCCP) and allosteric, or tetramerization, domains are
contained on a single polypeptide chain, although it has been
shown that some bacterial PCs have an ()4 structure with
the BC domain forming the  subunit and the CT and BCCP
domains forming the  subunit. Recently, the structures of
PC holoenzymes from Rhizobium etli [19] and Staphylococcus aureus [20, 21] have been determined. These structures,
along with site directed mutagenic studies [19], revealed that
the covalently attached biotin moves between the BC domain
of one subunit to the CT domain of a neighbouring subunit
located on an opposing polypeptide chain [19] thus giving
rise to a distinctive form of intersubunit catalysis. Furthermore, acetyl CoA, an allosteric activator of PC from several
sources, binds in the allosteric domain [19] and appears to
facilitate the interdomain movement of the BCCP and covalently attached biotin. While the activity of most vertebrate

A wealth of structural and kinetic data has been reported
for PC, contributing greatly to a detailed description of the
PC mechanism. The aim of this review is to focus specifically on the inhibition of PC as it relates to both the development of the current mechanistic model of PC activity and
the physiological regulation of the enzyme activity (Table 1).
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Fig. (1). Overall PC-catalysed reaction. A) Biotin carboxylation occurring in the BC domain. B) Carboxyl transfer step occurring in the CT
domain.
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Summary of the Different Intermediates and Inhibitors of Pyruvate Carboxylase Activities

Inhibition of PC through Interactions with Other Proteins
Name

Structure

Function/Mode of Inhibition

References

Avidin

• Tetrameric protein

• Binds to the biotin covalently attached to the
BCCP of PC with high affinity

[31-36]

Prohibitin
(Phb1)

• Mitochondrial

• Inhibition of anaplerotic activities of PC

[48-50]

• Mechanism of Phb1 inhibition unclear

chaperone protein

Inhibition of PC through Interactions with the Biotin Carboxylase (BC) Domain
Name

Structure

Carboxyphosphate

O
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• Putative intermediate formed during the ATPdependent carboxylation of biotin by bicarbonate
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[23, 38, 65]
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• Inhibition results from the increased strength of
the C-CH2-P bond

• Fluorescent analogue of ATP used in structurefunction studies

[64-66]

• Competitive inhibitor with respect to ATP for
chicken liver PC
• Can act as substrate for PC from some sources
albeit at a greatly reduced rate

OH OH
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• Competitive inhibitor with respect to ATP
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• Less effective inhibitor than adenosine possibly
due to active site interactions with negatively
charged phosphoryl group
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• Similar to 5’-AMP, number of phosphoryl
groups has greater effect on inhibition/nucleotide
binding than positioning of -phosphate
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• See Figure 4 for complete structures

UTP, CTP, TTP, ITP)

• Competitive inhibitors with respect to ATP

[33, 62]
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Table 1. contd….

Inhibition of PC through Interactions with the Biotin Carboxylase (BC) Domain
Name

Structure

Function/Mode of Inhibition
• Non-hydrolysable analogue of ATP

H2N
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• Used extensively in structure-function studies
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• Not phosphorylated in reverse reaction of BC
domain
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Inhibition of PC through Interactions with the Carboxyl Transferase (CT) Domain
Name

Structure

Pyruvate

O

Function/Mode of Inhibition

References

• Substrate for the carboxyl transfer reaction

[19, 22, 23]

• Enolisation of pyruvate promotes carboxylation

O
O

O

Oxamate

• Structural analogue of pyruvate
O

H2N

• CT domain active site

O

• Physiologically inhibits gluconeogensis
• Strong metal chealator

Oxalate
O

O

O

O

O

R

OH

• Physiological inhibition of anaplerosis
[35, 81-84]

• Competitive with respect to pyruvate

• Carcinogenic choloropropanol

(CPD)

• Inhibits gluconeogenesis through direct
inhibition of PC

Univalent and divalent
cations

• Replaces active metals in both the CT and BC
domains

Cl

[35, 62,
74-80]

• Some derivatives can act as carboxyl acceptors

O

3-chloro-1,2propanediol

• Binds to metal center similar to oxamate

• R = -F, -Cl, -Ph, -OH

O

Pyruvate derivatives

[35, 69-71]

• Coordinates to Mn2+ or Zn2+ metal center in the

OH

• Physiological regulation of PC activity throughfeedback inhibition

[82]

[69, 85-89]
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Table 1. contd….

Inhibition of PC through Interactions with the Allosteric Domain
Name

Function/Mode of Inhibition

Structure
O

L-aspartate
O

NH2

• Competitive inhibitor with respect to acetyl CoA

O

• Allosteric inhibitor of PC from vertebrates

O

• Non-competitive inhibitor with respect to acetyl
CoA and competitive with respect to pyruvate
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O
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• PC from various sources inhibited
• Physiological ratios of glutamate, acetyl CoA
and -ketoglutarate to regulate mitochondrial
activities

O
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105, 112115]

[116-122]

• Inhibits PC activity through antagonistic interactions with acetyl CoA
• No inhibition observed in the absence of acetyl
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O
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HO
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• Similar physiological function as aspartate
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O
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• Physiological regulatory feedback inhibition in
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While most of the inhibitors discussed herein have been used
to probe various aspects of PC structure and function, the
physiological relevance of several of these inhibitors have
also been examined in hopes of further understanding PC’s
role in the pathogenesis of Type II diabetes.
INHIBITION THROUGH
OTHER PROTEINS

[110]

S

O

acetoacetyl CoA

• Inhibition occurs when n = 4-10 in some sources
CoA

n

methylmalonyl CoA

• Phenyl acetyl CoA directly inhibits PC activity

INTERACTION

WITH

Inhibition by Avidin
Avidin, a protein abundant in egg whites, binds biotin
with a K D on the order of 10-15 M [24]; therefore, egg white-

• Strong competitive inhibitor with respect to
acetyl CoA in chicken and rat liver PC

[36, 110]

• Binds at a unique allosteric site

[115, 129]

• Noncompetitive inhibition with respect to all
substrates and acetyl CoA

rich diets have been used to induce experimental biotin deficiencies in animals [25]. A tetrameric protein (MW 63 kDa),
avidin is approximately cuboid in shape and contains one
biotin-binding site per subunit, with the biotin-binding sites
arranged in pairs on opposite faces of the cuboid structure
[26, 27] (Fig. 2). The potential use of avidin for the purification of biotinylated enzymes was quickly recognized; however, the affinity of avidin for biotin was so high that elution
of the enzymes was problematic. By dissociating avidin into
its constituent monomers before immobilizing them on
CNBR-Sepharose, thereby effectively reducing the affinity

Inhibitors of Pyruvate Carboxylase

of avidin for biotin, avidin could be used for the selective
isolation and purification of biotin-containing enzymes [2830].

A

B

15 A
Fig. (2)(A). Model of the quaternary structure of tetrameric avidin,
with one biotin molecule (in green) bound to each monomer. The
polypeptide backbones of the four monomers are each coloured
differently. Reproduced from [27] B) Diagramatic representation of
the structure of tetrameric avidin, showing the arrangement of the
biotin-binding sites in pairs on opposite sides of the cuboid structure. The pair of biotin-binding sites on the opposite 55 Å x 55 Å
faces of the molecule are shown as overlapping dotted circles. Reproduced with permission from Green, N.M., Konieczny, L., Toms,
E.J. and Valentine, R.C. (1971) Biochem J. 125: 781-791 [26] and
the Biochemical Society (http://www.biochemj.org).

The extremely high affinity of avidin for biotin also
makes it a potent inhibitor of biotin-dependent enzymes. The
first report of inhibition of PC by avidin dates back to 1960
[31] and, subsequently, Scrutton and co-workers used avidin
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as a probe of the enzymatic mechanism [32, 33]. In these
experiments, incubation of the enzyme with avidin was
shown to completely inhibit both [14C]pyruvate:oxaloacetate
and 32Pi:ATP isotopic exchange reactions [32], demonstrating the direct participation of biotin in these reactions.
Avidin only inhibits the [14C]ADP:ATP isotope exchange by
about 10%, indicating that biotin is not directly involved in
this reaction [33].
Assuming the avidin-inhibition of PC to be irreversible,
Scrutton and Utter [33] also performed the first reported kinetic investigation of the inhibition. Under pseudo-first order
conditions, analysis of the reaction order gave a stoichiometry of avidin: PC binding of 1.4, indicating that approximately one avidin molecule binds per enzymic PC tetramer
[33]. In an extension of these early kinetic studies, Duggleby
et al. [34] examined the kinetics of avidin-PC inhibition using methodologies developed for the study of slow, tightbinding inhibitors. Consequently, PC was added to reaction
mixtures containing fixed, saturating concentrations of the
substrates for pyruvate carboxylation, acetyl CoA and varying concentrations of avidin. By using the coupling enzyme
malate dehydrogenase and monitoring the reduction of
NADH [34], the development of the inhibition of the reaction was directly determined from the decrease in the initial
rates over the duration of the assay. The mode of inhibition
of PC by avidin could be sufficiently explained using a
scheme where the slow development of the inhibition was
due to the binding of avidin to PC, rather than the enzyme
undergoing a slow conformational change [34]. The second
order rate constant for avidin binding was determined to be
1.49  105 M-1s-1, which is several orders of magnitude lower
than the calculated diffusion-controled constant of 1.7  108
M-1s-1 and about 500 times lower than that for the binding of
free biotin to avidin [24], suggesting that strong steric factors
govern the rate of avidin binding to the covalently attached
biotin in PC. In the structures of Staphylococcus aureus PC
where the position of biotin has been determined [20, 21], it
is bound either in the active site of the CT domain or in a
pocket outside of the CT domain. Its other possible position
is in the active site of the BC domain. In any case, the biotin
does not appear to be easily accessible to the binding sites of
avidin.
The inhibition of PC by avidin was shown to be at least
partially reversible, as determined by the ability to reactivate
the enzyme initially incubated with a 2-5 fold molar excess
of avidin through the addition of 3000-5000 fold molar excess of free biotin [34]. Owing to the very slow nature of the
reactivation process, the time course of these experiments
was 16 hours during which there was an approximately 75%
loss of enzymic activity in control solutions of PC that did
not contain avidin. However, this loss of activity did not account for the small degree of reactivation that was observed
in the experimental sample and, thus, it was proposed that
PC in complex with avidin also underwent an inactivation
reaction [34]. Based on kinetic analysis of the reactivation of
the PC-avidin complex in the presence of free biotin, the
reactivation occurred at a rate (6-10  10-5 s-1) that was about
4-8 fold greater than that for the inactivation of the free enzyme (7.6  10-6 s-1) and for the dissociation of the avidin
from PC (1.42  10-5 s-1) [34]. This dissociation rate constant
of avidin from the tethered biotin is about 160 times greater
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than that for the dissociation of avidin and free biotin [24].
Thus the dissociation constant for the avidin-PC complex is
10-10 M, which is five orders of magnitude greater than that
determined for the avidin-biotin complex. One of several
factors contributing to the lower affinity of the biotinylated
enzyme for avidin, as compared to free biotin, may be the
covalent attachment of biotin to the side-chain of a conserved lysine residue in the BCCP domain of PC via the
formation of an amide bond with the carboxyl group of biotin. In free biotin, the carboxyl oxygen forms two hydrogen
bonds with residues in the biotin-binding site of avidin [26],
which could partially account for some of the decreased affinity. Even so, the large steric effect introduced by the attachment of the biotin to the enzyme, which subsequently
reduces the ability of avidin to bind to the covalently attached biotin as tightly as free biotin, is most likely responsible for increasing the overall dissociation constant determined for the PC-avidin complex.
In addition to measuring the simple kinetics of avidininhibition of PC, Scrutton and co-workers also examined the
effect various nucleotides had on the inhibition. It was found
that saturating concentrations of not only ATP, but also
ADP, 3’-AMP and 5’-AMP completely protected PC from
avidin inhibition [33]. The protective effect of these latter
two nucleotides, which do not promote biotin carboxylation,
strongly suggests that nucleotide binding to PC is liable to
reduce the accessibility of the tethered biotin to avidin by
inducing conformational changes which place biotin in the
BC domain. On the other hand, substrates and products of
the CT domain active site enhance the rate of avidin inhibition of PC by approximately 33% and 78% with saturating
pyruvate and oxaloacetate, respectively [35], indicating the
possibility that the binding of these molecules to PC increases the exposure of biotin to avidin by inducing the
movement of the tethered biotin from the BC domain to the
CT domain.
The effect of the allosteric activator, acetyl coenzyme A
(acetyl CoA), on the avidin inhibition of PC is more complicated. The rate of PC inactivation due to avidin- inhibition is
increased approximately 8-fold when acetyl CoA concentrations were kept between 10 and 200 μM, but at concentrations of above 200 μM, the rate of inactivation decreased
[36]. It is interesting to note that the acetyl CoA concentrations which resulted in an increased rate of PC inactivation
by avidin correspond to the same concentrations where acetyl CoA is most potent as an activator [36]. These results
further support the previous conjecture that a conformational
change in the PC structure, induced by the binding of the
allosteric activator and CT domain substrates, increases the
exposure of the tethered biotin to avidin. At higher concentrations of acetyl CoA, there is a counteracting conformational change, possibly due to the non-productive, partial
occupation of the nucleotide binding site [36], which imparts
a protective effect against avidin-inhibition, similar to that
observed in the presence of the various nucleotides. These
early avidin- inhibition studies were the first indication that
the movement of the BCCP and tethered biotin is dependent
on the presence of substrates and activators. Later kinetic
studies [23, 37, 38] and crystal structures [19, 20] confirmed
that the presence of BC and CT domain substrates and analogues dictate the location of the tethered biotin.

Zeczycki et al.

The stoichiometry of the avidin-PC binding was determined to be 1 mol /mol from both the kinetic measurements
of Scrutton and Utter [33] and titration experiments which
measured the displacement of 2-(4’-hydroxyazobenzene)
benzoic acid from the biotin binding sites in avidin by PC
[34]. Electron microscopy studies of PC revealed that the
enzyme subunits were arranged such that there appeared to
be an active site cleft running along the long axes with the
four subunits arranged in a tetrahedron-like configuration, as
shown in Fig. (3A) [39]. It was difficult to envisage how one
tetrameric avidin molecule could bind the four biotins of one
tetrameric PC molecule, leading to the conclusion that hetero-oligomers of avidin and PC may form. When Johannssen
et al. [40] examined the complexes of chicken liver PC and
avidin formed from varying ratios of the two molecules under the electron microscope, they observed the formation of
chain-like hetero-oligomers when the avidin: PC ratio was
between 2:1 and 1:2 in the presence of acetyl CoA (Fig. 3B).
Rohde et al. [41] obtained similar results using yeast PC. A
proposed model of these hetero-oligomers indicated that
avidin may act as a “glue,” thereby joining two PC tetramers,
with the biotin-binding sites on one face of the avidin
tetramer binding two biotins from one PC molecule and the
binding sites on the opposite face of the avidin molecule
binding two biotins from another PC tetramer (Fig. 3C) [40].
When the avidin:PC ratio was 9:1, PC-avidin complexes
which contained two avidin tetramers for every PC tetramer
were observed to be bound in a similar arrangement to those
previously described (Figs. 3D and E) [40]. X-ray crystal
structures of the PC holoenzyme from a variety of sources
have confirmed the arrangement of pairs of biotins on opposite faces of the PC tetramers [19-21].
Attwood et al. [42] showed that when PC was incubated
with avidin in a 1:1 ratio in the absence of acetyl CoA, only
a small number of shorter hetero-oligomers and few intact
PC tetramers were formed. In addition, the complexation of
PC with avidin was shown to stabilise the tetrameric structure of the enzyme, protecting it against dilution- dissociation [43]. This stabilization was further enhanced by the
presence of acetyl CoA, suggesting that the binding of the
activator induces PC to adopt a conformation that not only
facilitates the binding of avidin, thereby forming the heterooligomers, but also aids in the stabilization of the PC
tetramer. The proposed conformational and catalytic effects
of acetyl CoA binding to PC have been recently demonstrated in the X-ray crystallographic structure determined for
the PC holoenzyme from Rhizobium etli, which is activated
in the presence of acetyl CoA [19]. The R. etli PC structure
suggests the possibility that the binding of the allosteric activator promotes critical, global domain rearrangements which
facilitate inter-subunit catalysis via the movement of the
tethered biotin from the BC domain of one subunit to the CT
domain of the neighbouring subunit, [19]. Subunits without
acetyl CoA bound in the allosteric domain appear to adopt a
different conformation such that the inter-subunit catalysis
would be difficult [19]. These large conformational changes
induced by acetyl CoA binding could, in part, explain the
effect that acetyl CoA has on the formation of the PC-avidin
hetero-oligomers. Interestingly, high concentrations of pyruvate were also determined to have a similar effect on heterooligomer formation [42], although no structure of PC has yet
been obtained at these concentrations of pyruvate.
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B

C

D

E

Fig. (3)(A). Model of the tetrahedron-like arrangement of the subunits of PC derived from electron microscopic studies of the enzyme. Reproduced with permission from Mayer, F., Wallace, J.C., Keech, D.B. Further electron microscope studies on pyruvate carboxylase. Eur. J.
Biochem. 1980; 112: 265-272 [39] (Wiley-Blackwell). B) Electron micrograph of hetro-oligomers formed between chicken liver PC and
avidin at a ratio of avidin:PC of 1:2, in the presence of 0.25 mM acetyl CoA. The bar represents 40 nm. Reproduced with permission from
Johannssen, W., Attwood, P.V., Wallace, J.C., Keech, D.B. Localization of the active site of pyruvate carboxylase by electron microscopic
examination of avidin-enzyme complexes. Eur. J. Biochem. 1983; 133: 201-206 [40] (Wiley-Blackwell). C) Model of a hetero-oligomer of
avidin and PC, with the PC subunits shown in white and the avidin tetramers shown as grey cuboids, linking two PC tetramers together. Johannssen, W., Attwood, P.V., Wallace, J.C., Keech, D.B. Localisation of the active site of pyruvate carboxylase by electron microscopic
examination of avidin-enzyme complexes. Eur. J. Biochem. 1983; 133: 201-206 [40] (Wiley-Blackwell). D) Electron micrograph of complex
between a chicken liver PC tetramer and two avidin molecules, at a ratio of avidin:PC of 9:1. The avidin molecules are indicated by filled
triangles and the PC subunits by open triangles. The bar represents 16 nm. Johannssen, W., Attwood, P.V., Wallace, J.C., Keech, D.B.. Localisation of the active site of pyruvate carboxylase by electron microscopic examination of avidin-enzyme complexes. Eur. J. Biochem.
1983; 133: 201-206 [40] (Wiley-Blackwell). E) Model of the complex between a PC tetramer and two avidin molecules with the PC subunits
shown in white and the avidin tetramers shown as grey cuboids. Johannssen, W., Attwood, P.V., Wallace, J.C., Keech, D.B.. Localization of
the active site of pyruvate carboxylase by electron microscopic examination of avidin-enzyme complexes. Eur. J. Biochem. 1983; 133: 201206 [40] (Wiley-Blackwell).

Avidin has proven to be an extremely useful tool for the
examination of the biotin-dependence of the PC mechanism.
It has permitted the investigation of tethered biotin movement induced by the binding of substrates and inhibitors and
has suggested a possible structural role for the activator
in the stabilization of the quaternary enzyme structure. In

addition, the avidin-inhibition studies of PC enabled the
approximate determination of structural aspects of the
tetrameric enzyme, including the positioning of the biotins
on the subunits, which was especially important prior to
X-ray crystal structure determination.
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Inhibition by Prohibitin

Intermediate and Substrate Analogue Inhibitors

The prohibitins, Phb1 and Phb2, belong to a family of
highly conserved membrane-associated proteins which had
initially been identified as having putative regulatory roles in
eukaryotic cell proliferation, apoptosis, tumor suppression
and transcriptional activities [44, 45]. Furthermore, the
localization and abundance of Phb1 at the inner mitochondrial membrane [46] suggests its importance as a membranebound chaperone protein which aids in stabilizing newly
synthesized or imported mitochondrial proteins [47].
Sequence homology with other chaperone proteins, such
as HSP60, and computational predictions suggest the
N-terminal, transmembrane-spanning helix in Phb1 may
anchor the protein to the inner-mitochondrial membrane
[48]. Within the mitochondria, Phb1 and Phb2 form
high-molecular weight, ring-shaped Phb1/Phb2 complexes
which further facilitate their function as chaperone proteins
[45].

Ashman and Keech [58] used analogues of the putative
carboxyphosphate intermediate to probe the reaction mechanism of the BC domain in PC. In steady-state kinetic experiments, phosphonoacetic acid exhibited noncompetitive
inhibition with respect to MgATP (Ki = 0.5 mM) when the
initial rates of oxaloacetate formation were determined using
PC from sheep kidney. Similarly, phosphonoacetate was a
competitive inhibitor with respect to MgATP (Ki = 7.8 ± 1.8
mM) and a noncompetitive inhibitor with respect to HCO3 for the biotin carboxylation reaction catalysed by E. coli biotin carboxylase [59]. It was proposed that the inhibition was
due, in part, to the replacement of the highly labile C-O-P
bond in carboxyphosphate with a stable C-CH2-P bond.
Since phosphonoacetic acid is an isosteric and isoelectronic
analogue of carboxyphosphate, these inhibition studies lent
further support to the proposed mechanism whereby biotin
carboxylation occurs via the reversible formation of the
unstable, mixed-anhydride intermediate.

Phb1 and PC were identified as two of several mitochondrial proteins isolated from lipolytically stimulated 3T3-L1
adipocyte lipid droplets [49], demonstrating that adipocytes
contain lipid metabolic enzymes and proteins. In vivo and in
vitro studies using mice adipocytes revealed that Phb1 is a
potent, specific inhibitor of PC and, through this inhibition,
attenuates both fatty acid and insulin-stimulated glucose oxidation [50]. The insulin-stimulated release of 14CO2 from
uniformly labeled 14C-glucose was markedly inhibited in the
presence of 2 nM prohibitin and a Ki of approximately 4 nM
for Phb1 inhibition of PC in vivo was determined. Inhibition
of fatty acid oxidation in the presence of Phb1 in the mouse
adipocytes was most likely due to the lack of available oxaloacetate resulting from the almost complete inhibition of
PC. By monitoring the incorporation of NaH14CO3 into oxaloacetate, Vessal and co-workers further established that
Phb1 potently inhibited (Ki  5 nM) PC isolated from the
adipocyte lysate [50]. While the mechanism of PC inhibition
by Phb1 is not clearly understood, both in vivo and in vitro
studies indicate that Phb1 that has been translocated into the
mitochondria effectively inhibits anaplerosis through interactions with PC. Whether this inhibition has any physiological
relevance, or if Phb2 and the Phb1/Phb2 complex exhibit the
same inhibitory effects on PC remains uncertain [48].
INHIBITION
DOMAIN

OF THE BIOTIN

CARBOXYLASE

The reaction catalysed in the BC domain, namely the
ATP-dependent carboxylation of biotin by bicarbonate, is
common to biotin-dependent carboxylases, with the exception of transcarboxylase [22]. Recent studies have focused
on the inhibition of the biotin carboxylase subunit of acetyl
CoA carboxylase from E. coli, which exists as a homodimer
in solution and utilizes free biotin as a substrate [51].
Reaction-based intermediate analogues [52, 53] and small
molecules, determined from a fragment-based screening approach [54-56], have been shown to successfully inhibit
E. coli biotin carboxylase. Since many of the examples of
biotin carboxylase inhibition have been extensively discussed in a previous review [57], only those studies which
involve the inhibition of the biotin carboxylase domain in the
context of the PC holoenzyme will be discussed here.

Carbamoyl phosphate, a structural analogue of carboxyphosphate, will directly phosphorylate ADP in reactions
catalyzed by acetyl CoA carboxylase from E. coli [60] and
PC [58], allowing for the examination of the partial reverse
reaction of the BC domain without complications due to biotin carboxylation. Inhibition of the PC-catalyzed phosphorylation of ADP with carbamoyl phosphate [38] and the bicarbonate-dependent ATP cleavage [61] was observed in the
presence of oxamate, a substrate analogue of pyruvate (see
inhibition of the CT domain reactions). Even though oxamate has been shown to bind in the CT domain, a hyperbolic, non-competitive inhibition with respect to carbamoyl
phosphate was observed in those reactions catalyzed by PC
from chicken liver [38]. Correspondingly, the addition of 20
mM of oxamate resulted in a 98% reduction in the rate of the
PC-catalyzed bicarbonate-dependent ATP cleavage [61]. The
non-competitive nature of the oxamate inhibition of the BC
domain reactions further confirmed initial avidin inhibition
studies [34] and later kinetic studies by Goodall et al. [37],
which suggested that the binding of oxamate in the CT domain active site induces the translocation of biotin from the
BC domain to the CT domain. While not directly involved,
the presence of free biotin has been shown to have a stimulatory effect on both the ADP phosphorylation and bicarbonate-dependent ATP cleavage reactions. Consequently, the
oxamate-induced removal of the tethered biotin from the BC
domain explains the apparent inhibition by oxamate.
Nucleoside and Nucleotide Inhibitors
While MgATP is the physiological nucleotide substrate
for the pyruvate carboxylation reaction of PC (Km of the order of 40-60 μM), MgdATP is also an effective substrate,
with a Km of approximately 70 μM [33, 62]. MgGTP,
MgUTP, MgCTP, MgTTP and MgITP (Fig. 4) have all been
reported to act as competitive inhibitors of pyruvate carboxylation with respect to MgATP, giving Ki values in the range
of 0.7-0.9 mM [62]. However, Scrutton and Utter [33] reported them to be non-competitive inhibitors of the
[32P]ATP:ADP isotope exchange reactions with chicken liver
PC. As McClure et al. [62] pointed out, the non-competitive
nature of the inhibition may have been due to the fact that
free nucleotides, rather than those complexed with Mg2+,
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Fig. (4). Structures of the various nucleotide and nucleoside inhibitors of PC.

were used in the inhibition studies. Interestingly, the Ki values reported by Scrutton and Utter [33] are approximately an
order of magnitude lower than those reported by McClure et
al. [62], suggesting that un-complexed nucleotides may bind
with a higher affinity than the MgNTP complexes.
Both 5’-AMP and 3’, 5’-cyclic AMP have been reported
to be competitive inhibitors with respect to MgATP [62]
with PC isolated from rat liver (Ki = 1.3 mM and 1.0 mM,
respectively). Based on these steady-state kinetic studies, it
was proposed that that the reduction in the number of phosphoryl groups, as compared to ATP, had a greater effect on
the nucleotide binding affinity than the positioning of the phosphate did. In light of these results, it is somewhat surprising that adenosine is an extremely potent competitive
inhibitor with respect to MgATP [62, 63] (Ki = 0.08-0.09
mM). In the R. etli PC holoenzyme structure with ATP--S
bound in the BC domain, there are seven potential hydrogenbonding interactions between the adenosine portion of ATP-S and residues in the active site (Fig. 5) [19]. These observed interactions, combined with the adenosine inhibition
kinetics, support the proposal that a significant amount of the
nucleotide binding energy in the BC domain comes from
interactions between the active site residues and the adeno-

sine moiety of MgATP. Therefore, it can be argued that the
negatively charged phosphoryl group of 5’-AMP or 3’-AMP
introduces unfavorable electrostatic interactions within the
active site that result in the decreased affinity of PC for these
molecules as compared to adenosine. In another study, 5’AMP (Ki = 9.3 mM) and 3’-AMP (Ki = 13 mM) were both
found to be non-competitive inhibitors of chicken liver PC
[33], suggesting that in this case the nucleotides were binding with low affinity to a site outside the normal substrate
binding site, possibly part of the acetyl CoA binding site.
Analogues of ATP, such as ATP--S which cannot act as
a substrate, have been used in structure-function studies of
PC [19]. The Mg2+-complex of the fluorescent ATP analogue, formycin A-5’-triphosphate (MgFTP), is a competitive inhibitor of chicken liver PC with respect to MgATP (K i
= 50 μM) [64]. However, sheep liver PC can utilize MgFTP
as a substrate for pyruvate carboxylation, albeit with a kcat
that is one-twentieth of that with MgATP as a substrate and a
Km one-third of that for MgATP [64]. Since binding to PC
enhances the fluorescence of MgFTP approximately 2-fold,
FTP and FDP have been extensively used to study the presteady state kinetics of nucleotide binding to PC in stoppedflow experiments [65, 66]. The second-order binding rate
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Fig. (5). Model of part of the active site of the CT domain of Rhizobium etli PC showing the potential binding interactions between ATP--S
and residues in the active site. Reproduced with from [19].

constant of MgFTP was determined to be 2.6  106 M-1 s-1
and the dissociation rate constant was 82 s-1 in experiments
using chicken liver PC [66]. The fluorescence of PC-bound
MgFTP has also been used to measure the effects of other
substrates and activators on nucleotide binding [66].

from the BC domain to the CT domain [37]. Furthermore,
oxamate stimulates the decarboxylation of carboxybiotin,
allowing for the examination of the steady-state kinetics of
the reverse reaction of the CT domain in isolation from reactions occurring in the BC domain [23, 68].

Analogues of ADP have also been used to probe the
mechanism of the BC domain. Ashman and Keech [58]
found that , -methylene adenosine diphosphate
(Ap(CH2)p) and adenosine 5’-phosphosulfate (APS) were
competitive inhibitors for pyruvate carboxylation with respect to MgATP in reactions catalysed by sheep kidney PC.
The Ki (0.58 mM) determined for Ap(CH2)p was nearly
three times lower than that of MgADP, indicating that the
enzyme had a high affinity for this analogue. While APS
also exhibited competitive inhibition with respect to
MgATP, the Ki value of 3 mM signified the enzyme had a
much lower affinity for the analogue. Additionally, it was
determined that PC would not catalyse the phosphorylation
of these analogues in the full reverse reaction. Similar to
conclusions drawn by McClure [62] these data strongly suggest that substitution at the ,  position of ADP is less critical for catalysis than substitutions at the position of bond
cleavage/formation.

Using chicken liver PC and monitoring the steady-state
kinetics of pyruvate carboxylation with the malate dehydrogenase coupled assay system, Scrutton et al. [69] determined
that oxamate was a non-competitive inhibitor with respect to
pyruvate in the overall pyruvate carboxylation reaction (Ki =
1.6 mM). Previous pulsed NMR experiments examined the
effect of oxamate on the relaxation rate of water protons coordinated to the paramagnetic Mn2+-metal centre in the CT
domain of PC from chicken liver mitochondria [35]. In this
way, the coordination of substrates, inhibitors and products
to the paramagnetic metal-center could be determined, allowing for the direct examination of the inhibition kinetics.
Based on the decreased enhancement of the water protons
relaxation rate, due to their displacement by the substrate
analogue inhibitors, oxamate was proposed to chelate to the
Mn2+-metal centre in the CT domain. Uncompetitive oxamate inhibition with respect to pyruvate was observed for
the pyruvate carboxylation reaction, but the inhibition was
competitive when determined as a function of oxaloacetate
for the reverse reaction. From the analysis of the proton relaxation data and the effect of oxamate on PC inactivation by
avidin, a dissociation constant of K D = 1.45 mM was determined for the oxamate-enzyme complex. Direct coordination
of oxamate to the Mn2+-metal centre, as suggested by the
pulsed NMR experiments, would be expected to give competitive inhibition patterns with respect to pyruvate, as oxamate would presumably prevent the coordination and subsequent enolization of pyruvate. The uncompetitive nature of
the inhibition could possibly be explained if oxamate forms
an enzyme-inhibitor complex where the carboxylation of
biotin is kinetically insignificant and pyruvate will only interact appreciably with the enzyme once biotin is carboxylated. Although it is difficult to envision how oxamate prevents the carboxylation of the biotin at low concentrations,
the movement and requisition of the tethered biotin to the CT

INHIBITION OF THE CARBOXYL TRANSFERASE
DOMAIN
In the CT domain, carboxybiotin is decarboxylated and a
strictly conserved Thr residue is proposed to facilitate the
transfer of a proton from pyruvate to biotin, thereby forming
the highly nucleophilic enol-pyruvate [23]. Pyruvate analogues and several dicarboxylic acids and their derivatives
have been shown to be specific, reversible inhibitors of the
carboxyl transfer step, usually through interactions with the
Mn2+- or Zn2+-metal centre contained in the CT domain active site.
Oxamate
A potent inhibitor of lactate dehydrogenase [67], oxamate is a structural analogue of pyruvate which binds in the
CT domain and induces the movement of the tethered biotin
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domain, induced by the coordination of oxamate to Mn2+,
may be faster than the partially rate-limiting carboxylation
reaction in the BC domain.
To assess the physiological relevance of oxamate inhibition of PC on the rates of hepatic gluconeogenesis, MartinRequero and co-workers analysed the effect of added oxamate on the gluconeogenic flux and PC activity in perfused
rat livers, isolated hepatocyte suspensions [70] and isolated
rat liver mitochondria [71]. In these studies, the resulting
concentrations of metabolic intermediates were used to determine the effect of oxamate on gluconeogenesis, while the
rate of pyruvate carboxylation was approximated from a determination of H14CO3- incorporation into the metabolites
isolated from mitochondrial extracts. In perfused rat livers
and isolated hepatocytes [70], the presence of oxamate resulted in a decrease in the concentrations of all metabolites
after pyruvate, indicating that the inhibitory effect on
gluconeogenesis was due, in part, to the inhibition of PC.
Oxamate was determined to be a competitive inhibitor of
gluconeogenesis at concentrations of pyruvate less than 0.4
mM and had little effect on glucose production at concentrations of pyruvate greater than 0.4 mM. These results are
somewhat surprising in light of studies performed with the
isolated rat liver [62] and chicken liver enzymes (above),
both of which showed an uncompetitive oxamate inhibition
when pyruvate was the varied substrate. The discrepancy
between the type of inhibition exerted by oxamate in the
isolated enzymes and in the perfused liver studies suggested
that oxamate may be inhibiting not only PC but also another
enzyme whose mitochondrial function is directly related to
pyruvate utilization in gluconeogenesis.
In an extension of these initial studies, oxamate was determined to exhibit a mixed-type inhibition pattern with respect to pyruvate in isolated mitochondria from rat liver [71].
Similar to the previous study, oxamate inhibited pyruvate
carboxylation by approximately 40% at low pyruvate concentrations, but had no discernible effect on the net gluconeogenic flux at concentrations of pyruvate greater than
0.4 mM. Varying HCO3- and determining the rates of pyruvate carboxylation in the presence of oxamate resulted in a
non-competitive inhibition pattern. The lack of substantial
inhibition at high concentrations of pyruvate and competitive
inhibition with respect to pyruvate at low concentrations
strongly suggested that oxamate inhibition of gluconeogenesis in the isolated mitochondria resulted from the noncompetitive inhibition of PC and the competitive inhibition
of the mitochondrial pyruvate translocator protein, which
facilitates pyruvate transport across the mitochondrial membrane [71].
Oxalate
Oxalate, an inhibitor of both lactate dehydrogenase [72]
and transcarboxylase [73], was also found to be an effective
inhibitor for PC from a variety of sources. For example, oxalate was a non-competitive inhibitor with respect to HCO3 (Ki = 60-300 M [62]) in rat liver PC and a non-competitive
inhibitor with respect to pyruvate (Ki = 70 M) for PC isolated from yeast [74] as well as PC from rat liver (Ki = 50130 M [62]) and chicken liver (Ki = 12 M) [69]. Barden
and co-workers [75] extended the initial kinetic studies of
oxalate inhibition of chicken liver PC. Steady-state kinetic
analysis determined that, while the inhibition was uncom-
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petitive with respect to pyruvate for the pyruvate carboxylation reaction, oxalate inhibition was competitive with respect
to oxaloacetate for the decarboxylation reaction, confirming
results previously obtained from pulsed NMR experiments
[35]. Avidin inactivation studies in the presence of oxalate
[35] provided a dissociation constant of 8.9 M for the oxalate-PC complex, nearly three orders of magnitude lower
than that determined for oxamate, indicating that the bidentate chelation of oxalate to the Mn2+-metal centre most likely
increases the affinity of the enzyme for the inhibitor.
McClure [62] probed the effect that the inhibition of the CT
domain with oxalate had on the affinity for substrates in the
BC domain by studying the steady-state kinetics of the pyruvate carboxylase reaction catalyzed by PC from rat liver. As
expected, oxalate was also found to be a non-competitive
inhibitor with respect to MgATP.
Similar to oxamate, oxalate also inhibits gluconeogenesis
in isolated mitochondria and hepatocytes. Dennis et al. [76]
determined that oxalate had no inhibitory effect on pyruvate
transportation into the mitochondria; therefore the inhibition
of glucose production was presumably due to the direct
inhibition of PC by oxalate. In subsequent studies, both
Yount and Harris [77] and Tonon and co-workers [78] found
that the infusion of isolated rat hepatocytes with oxalate
significantly inhibited hepatic gluconeogenesis from alanine,
pyruvate and lactate as determined from the concentrations
of the metabolic intermediates. In bicarbonate-deficient
media, where PC activity became completely rate-limiting,
the inhibition of glucose production by oxalate was even
more apparent, further supporting the idea that oxalate was
directly inhibiting PC activity [77]. The addition of 100 M
of oxalate reduced the steady-state levels of oxaloacetate by
48% in rat liver cells [79] and physiological concentrations
of oxalate (50-100 M) were found to partially impair
the mitochondrial metabolism of pyruvate, resulting in
decreased anaplerosis due to the oxalate inhibition of PC
[80].
Pyruvate Derivatives
Many of the derivatives of pyruvate, including fluoro and
chloropyruvate, not only act as carboxyl acceptors for the
PC-catalyzed carboxylation reaction but can also act as effective, specific inhibitors of the carboxyl transfer reaction.
Scrutton et al. [69] examined the inhibition of the carboxyl
transfer reaction using fluoropyruvate (Ki = 0.17 mM) and
phenylpyruvate (Ki = 0.48 mM). Both analogues were noncompetitive inhibitors with respect to pyruvate when the
initial rates of oxaloacetate formation were determined.
Pulsed NMR studies [35] suggested that fluoropyruvate inhibited the carboxyl transfer in a mechanism similar to oxamate and oxalate where the direct coordination of the analogue to the cationic-metal centre partially prevented pyruvate coordination and subsequent enolization.
In rat brain mitochondria [81], fluoropyruvate was determined to inhibit anaplerosis by not only the direct inhibition of PC, but also by lowering the available concentration
of acetyl CoA in the mitochondria. The addition of 0.5 mM
of fluoropyruvate resulted in a 95% inhibition of cerebral PC
activity as determined from the initial rate of oxaloacetate
formation using H14CO3-. In order to determine if the potent
inhibition of the mitochondrial activity was due solely to the
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inhibition of PC, the activities of the isolated enzyme, treated
with varying concentrations of fluoropyruvate were determined. The competitive inhibition of the isolated PC by
fluoropyruvate was mild; only a 47 % inhibition of PC activity was observed with the addition of 5 mM of fluoropyruvate which accounted for only a fraction of the inhibition
observed in the intact cerebral mitochondria. The addition of
10 M of acetyl CoA to the reactions completely reversed
the inhibition of pyruvate carboxylation at low concentrations of fluoropyruvate. It is possible that, in the cerebral
mitochondria, the inhibitory effect of fluoropyruvate manifests itself in two ways, namely through the direct, competitive inhibition of PC and through the formation of fluoroacetyl CoA, which thereby limits the availability of the potent
PC activator, acetyl CoA.
The investigation of hepatic gluconeogenesis inhibition
by fluoro- and chloropyruvate, chloroacetic acid and 3chloro-1,2-propanediol (CPD), a carcinogenic chloropropanol, in rat liver slices demonstrated that chloropyruvate
was a more potent inhibitor of PC activity than the other
analogues examined [82]. High doses of CPD, which is proposed to be metabolized to either chloropyruvate or
chloroacetic acid also inhibited gluconeogenesis. The addition of 10 mM of chloropyruvate resulted in the nearly complete inhibition of glucose production (> 95%), compared to
85% and 54% inhibition using 10 mM of fluoropyruvate and
chloroacetic acid, respectively. Chloropyruvate was also a
more potent inhibitor as compared to CPD, although a 45%
reduction in PC activity was observed in the presence of 10
mM of CPD. Further experiments confirmed that the inhibition of gluconeogenesis was in fact due to the direct modulation of PC activity in the rat liver slices [82].
PC isolated from Thiobacillus novellus, a methylotrophic
chemiolithautotroph, is allostericaly activated by acetyl CoA
and inhibited by hydroxypyruvate [83]. Aspartate, glutamate
and other dicarboxylic acids, such as -ketoglutarate, had no
effect on oxaloacetate production [84]. The addition of 2
mM of hydroxypyruvate resulted in a 35% reduction in pyruvate carboxylating ability. Initial rate studies determined
that this pyruvate derivative was a non-competitive inhibitor
with respect to HCO3- (Ki = 7.1 mM), MgATP (Ki = 5.5
mM), and, surprisingly, pyruvate (Ki = 5.4 mM), indicating
that the binding of these substrates did not significantly affect the enzyme’s affinity for hydroxypyruvate. It is interesting to note that hydroxypyruvate was also an uncompetitive
inhibitor with respect to acetyl CoA (Ki = 3.6 mM) and reduced the Hill coefficient for acetyl CoA binding 2-fold. The
inhibition patterns observed with respect to acetyl CoA suggested that the reversible binding of the activator to the enzyme increased the affinity of the inhibitor for PC. While
somewhat uncommon that PC from Thiobacillus novellus is
only mildly inhibited by hydroxypyruvate, it is further evidence that substrate derivatives, like fluoropyruvate, chloropyruvate and hydroxypyruvate, appear to down-regulate PC
gluconeogenic activity in most cases, rather than completely
inhibiting the enzyme.
INHIBITION
CATIONS

BY

UNIVALENT AND DIVALENT

In the PC-catalysed pyruvate carboxylation reaction,
there appears to be an absolute mechanistic requirement of
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two Mg2+ ions, which are sequestered into the BC domain
active site via the complexation to ATP [19]. There is also a
need for a divalent cation in the CT domain, generally Mn2+
or Zn2+, which is proposed to act as a Lewis acid and promote the enolization of pyruvate [23, 69]. Although PC from
various sources exhibit similar catalytic properties, there is a
wide difference in responses to activation and inhibition by
various cations including Ca2+, Zn2+, Mn2+, Li2+ and Na+.
While this review does not attempt to be comprehensive in
its discussion of the inhibition of PC by univalent and divalent cations, some of the more detailed studies of the effects
of these inhibitors will be discussed.
Zn2+, Cu2+ and Cd2+ are potent inhibitors of chicken liver
PC [69], most likely due to the formation of inactive metalATP complexes. Similarly, pyruvate carboxylation catalyzed
by PC from baker’s yeast [85] is effectively inhibited by the
addition of Sr2+, Co2+, Cu2+, and Sn2+. Interestingly, the addition of 5 M of Na+ resulted in a 60% decrease in the rates
of the Pi:ATP exchange reaction in yeast PC, indicating that
the inhibitory effect of the monovalent cation was on the
biotin carboxylation reaction rather than the carboxyl transfer to pyruvate. Mn2+ was inhibitory in rat liver PC [86] at
concentrations above 2 mM but, while appreciable concentrations of free Mn2+ inhibited pyruvate carboxylation, the
presence of Mg2+ fully restored PC activity. Zn2+ was also a
potent inhibitor of rat liver PC [86], where the addition of
0.06 mM of ZnSO4 completely and irreversibly inactivated
the enzyme. Further experiments suggested that even in the
presence of saturating Mg2+, the two Zn2+ ions remained coordinated to the enzyme. Unlike chicken liver PC, which is
activated by the addition of Co2+ [87], rat liver PC is inhibited by the cation [86].
Barden and Scrutton [88] extended the initial studies of
cation inhibition of PC from chicken liver. While a majority
of univalent cations, including K+, Rb+ and Cs+, were activators of the overall pyruvate carboxylation reaction, Li+ inhibited not only the K+-stimulated activity, but also PC activity
in the absence of any activators. Li+ was determined to be a
non-competitive inhibitor (Ki = 42 ± 3 mM) with respect to
K+ for the K+-stimulated pyruvate carboxylation, suggesting
that Li+ is coordinating to sites inaccessible to K+.
Physiologically, while the inhibition of rat liver PC by
Co2+ and Mn2+ appears to be of little consequence, the inhibition of PC activity by Ca2+ as observed in isolated rat liver
[86, 88] and in intact rat liver mitochondria [89] may be a
means by which the mitochondria regulates gluconeogenesis.
PC activity in the intact mitochondria was determined by
measuring the release of 14CO2 from pyruvate-1-14C, which
allowed for the determination of both PC and pyruvate dehydrogenase activity, as well as directly measuring the concentrations of the TCA cycle intermediates. Based on this
investigation, Kimmich and Rasmussen [89] determined that
Ca2+ was a potent and specific inhibitor of PC in the intact
mitochondria with the addition of 100 M of Ca2+ resulting
in a 75% loss of PC activity. The extent of Ca2+ inhibition
was dependent on the Mg2+/Ca2+ ratio, prompting further
studies by Wimhurst and Manchester [86] which examined
the inhibitory effect of Ca2+ at varying concentrations of
Mg2+ (3.2 and 8.0 mM) using isolated rat liver PC. Ca2+ was
a competitive inhibitor with respect to Mg2+ (Ki = 0.38 mM),
suggesting the displacement of Mg2+ in the ATP binding site
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with Ca2+. PC was less susceptible to Ca2+ inhibition when
Mn2+ was used instead of Mg2+, resulting in only 20% inhibition in the presence of 1 mM of Ca2+ as opposed to 60% inhibition when Mg2+ was used as the enzyme activator [86].
The interplay between Ca2+ inhibition and Mg2+ activation of
PC suggests that changes in the intracellular concentrations
of these ions may have a role in regulating gluconeogenesis
via the direct inhibition or activation of PC [89].
INHIBITORS OF THE ALLOSTERIC SITE
Acetyl Coenzyme A is an allosteric activator of many PC
enzymes. Recent structural studies reveal that the acetyl CoA
binding site is centered in an allosteric domain, also referred
to as the tetramerization domain, which is remote from either
of the two active sites [19, 20]. A number of PC inhibitors
exert their influence on the enzyme through interactions in
the allosteric domain, either by competing with acetyl-CoA
and/or by modulating the cooperativity of acetyl CoA binding.
Dicarboxylate Allosteric Inhibitors: Aspartate, Glutamate and -Ketoglutarate
Aspartate, -ketoglutarate and glutamate are allosteric
inhibitors of PC that, under physiological conditions, provide
regulatory feedback inhibition in response to the increased
production of TCA cycle intermediates. Aspartate serves as
an allosteric inhibitor of microbial and fungal PC, while glutamate serves this same role in PC isolated from vertebrate
sources [90-93].
Aspartate Inhibition of Microbial PC
PC from Saccharomyces cerevisiae is activated by acetyl
CoA and inhibited by L-aspartate in an allosteric manner. In
PC from S. cerevisiae, as in most PC enzymes inhibited by
aspartate, the mode of inhibition occurs through an antagonistic effect on the activation by acyl CoA derivatives [9397]. Aspartate increases the Hill coefficient for acetyl CoA
and, conversely, acetyl CoA increases the Hill coefficient for
aspartate [95-97]. The aspartate inhibition kinetics are complex, typically exhibiting non-classical behaviour. PC from
S. cerevisiae is inhibited by aspartate in the presence of the
activators acetyl CoA or palmitoyl CoA, with the addition of
10 mM aspartate resulting in a 70- to 80-fold increase in the
activator concentration required for half-maximal activation
[96]. In fungi, the aspartate allosteric binding site appears to
be distinct from the site of acetyl CoA binding, despite the
observed competitive inhibition of acetyl CoA by aspartate
[95, 98]. The suggestion of independent binding sites is supported by the fact that the loss of activation by acetyl CoA
upon incubation of PC with trinitrobenzene sulfonate does
not correlate with any concomitant loss of inhibition by aspartate [93, 98, 99]. PC from the fungus Aspergillus nidulans
has also been shown to be partially inhibited by aspartate
[98, 100]]. Aspartate is a competitive inhibitor with respect
to acetyl CoA and is non-competitive with respect to
MgATP and pyruvate [98], consistent with a binding site
located in the allosteric domain of the enzyme. Aspartate has
an IC50 = 0.6 mM and displays positive cooperativity (Hill
coefficient = 2.1) in the absence of acetyl-CoA. Contrary to
the effect of acetyl CoA on the cooperativity of aspartate in
most other PC enzymes, the Hill coefficient is reduced in PC
from A. nidulans in the presence of 20 μM acetyl CoA. Both
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aspartate and glutamate inhibit the cytosolic isoenzyme of
PC from Rhizopus arrhizus, though it is likely that glutamate
exerts its affect by acting as an analogue of aspartate [101].
The reduced stringency in discriminating between aspartate
and glutamate appears to be unique to R. arrhizus PC.
Bacterial PC enzymes are also reported to be inhibited by
L-aspartate, though there is significant variation among the
bacterial enzymes. PC from Pseudomonas citronellis [102,
103], Pseudomonas fluorescens [104], Methanosarcina
barkeri [105] and Azotobacter vinelandii [106] are arranged
in an ()4 structure where two polypeptide chains contribute to the protomer. PC with this ()4 structure are neither
activated by acetyl CoA nor inhibited by aspartate. Conversely, bacterial PC enzymes that consist of four identical
subunits ()4, similar to the arrangement in the PC enzymes
isolated from eukaryotic sources, are affected by the presence of acetyl CoA and aspartate. For example, the bacterial
()4 enzymes isolated from thermophilic Bacillus [93], Arthrobacter globiformis [107], Rhodobacter capsulatus [108]
and Sinorhizobium meliloti [109] are allosterically activated
by acetyl CoA and allosterically inhibited by aspartate. This
suggests that the aspartate binding site in the ()4 PC enzymes is most likely located in the relatively small allosteric
domain, near the acetyl CoA binding site [19, 21]. While the
binding site for acetyl CoA has been identified in X-ray crystal structures of bacterial ()4 enzymes [19, 21], the precise
binding site for aspartate has yet to be delineated. The concentration of aspartate required for significant inhibition of
PC is relatively high (~5 to 10 mM), but it has been suggested that these concentrations are, nonetheless, physiologically relevant [95].
Glutamate Inhibition of Vertebrate PC
While PC isolated from vertebrate sources is insensitive
to aspartate, they are allosterically inhibited by L-glutamate
[90, 110, 111] Scrutton and White [99] reported approximately 50% inhibition of the acetyl CoA activated rate of
oxaloacetate synthesis in the presence of 5 mM glutamate for
PC isolated from both chicken liver and rat liver. No inhibition was observed in the presence of 5 mM aspartate. Comparable concentrations of glutamate have been measured in
rat liver [112, 113], suggesting that glutamate provides a
physiological mechanism for the negative feedback regulation of PC activity. Glutamate appears to be a non-classical,
non-competitive inhibitor with respect to acetyl CoA with
an apparent Ki of 3.8 mM for chicken liver PC and 4.7 mM
for rat liver PC. The Hill coefficient is insensitive to acetyl
CoA and approximates to a value of 1 at all concentrations
of acetyl CoA [90]. For both the chicken and rat liver PC,
glutamate acts as a competitive inhibitor with respect to
pyruvate, a non-competitive inhibitor with respect to
bicarbonate and an uncompetitive inhibitor with respect to
MgATP [90]. A similar pattern of inhibition is observed with
respect to the substrates of human liver PC [111].
Inhibition by -Ketoglutarate
Allosteric inhibition of PC by -ketoglutarate has been
characterized for PC enzymes from a number of sources,
including avian liver [90], the fungi A. nidulans and S. cerevisiae [93, 98], and the prokaryotes Bacillus [93] and
Rhodobacter capsulatus [108]. Modest inhibition (~15%)
has also been reported in PCs isolated from the methanogens
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Methanosarcina barkeri [105] and Methanobacterium thermoautotrophicum [114]. Unlike PC inhibition by glutamate
and aspartate, inhibition by -ketoglutarate appears to be
widely distributed, but not universal. Several dicarboxylic
and tricarboxylic acids are inhibitory for PC from R. arrhizus
with 2-oxoadipate exhibiting many similar characteristics to
-ketoglutarate [101]. Inhibition properties suggest that 2oxoadipate and aspartate inhibit the enzyme by binding to
independent regulatory sites. PC from A. nidulans has been
shown to be inhibited by the binding of -ketoglutarate at a
distinct allosteric site removed from the site of action for Laspartate. [91, 98, 100]. Similarly, PC from avian liver is
also inhibited by -ketoglutarate binding at a distinct inhibitory site from that of glutamate [90]. The -ketoglutarate
inhibition has been extensively characterized in chicken liver
PC, where a Hill coefficient of 1.5 and an apparent Ki of 3
mM has been reported [90]. As the acetyl CoA concentration
is increased to saturation, the Hill coefficient for ketoglutarate increases to ~3. Conversely, the concentration
of -ketoglutarate has no effect on the Hill coefficient for
acetyl CoA. The inhibitory site for -ketoglutarate in
chicken liver is also proposed to be distinct from the acetyl
CoA binding site, since -ketoglutarate inhibition is insensitive to reagents that eliminate acetyl CoA activation [90].
The presence of separate allosteric binding sites for acetyl
CoA, -ketoglutarate and glutamate in the chicken liver enzyme led Scrutton and White [90] to propose that the physiological ratio of these metabolites permits regulatory control
over chicken liver PC activity in the mitochondria [115].
Chlorothricin
Chlorothricin is a macrolide-type antibiotic produced by
Streptomyces antibioticus strain Tü 99 [116, 117]. It is a
freely reversible competitive inhibitor of PC from Bacillus
stearothermophilus with an apparent Ki of 173 μM that increases the Hill coefficient for acetyl CoA from 2 to 3 [118].
Chlorothricin’s effect on Bacillus stearothermophilus PC
activity is limited to its antagonistic interaction with acetyl
CoA, as it does not inhibit PC in the absence of acetyl CoA
[118]. However, chlorothricin does inhibit both Azotobacter
vinelandii PC and rat liver PC in the presence and absence of
acetyl CoA [119]. Chlorothricin is noncompetitive with respect to both MgATP and pyruvate and suppresses substrate
activation by pyruvate while promoting MgATP substrate
inhibition [118, 119]. These results lead Schindler and Zahner [118] to propose that chlorothricin binding to PC stabilizes a less active conformation of the enzyme.
Chlorothricin also reversibly inhibits PC from Bacillus
subtilis, rat liver, chicken liver and Azotobacter vinelandii
[118-120], with IC50 values ranging from 0.12 to 0.50 mM.
The antibiotic has a greater affect on PC enzymes that have a
more pronounced sensitivity to acetyl CoA activation. The
aglycone of chlorothricin, or the chlorothricolide methyl
ester, is also inhibitory against all enzymes from B.
stearothermophilus, A. vinelandii, chicken liver and rat liver,
though to a lesser degree [119]. The -methyl rhamnoside
portion of chlorothricin did not display any inhibitory properties, indicating that the aglycone portion of the molecule is
the primary site of interaction. It is noteworthy that intact
chlorothricin displays cooperative inhibition of the acetyl
CoA activation in the vertebrate liver PC enzymes, while the
aglycone portion of chlorothricin does not exhibit coopera-
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tivity [119]. Chlorothricin is a non-competitive inhibitor with
respect to acetyl CoA in PC isolated from vertebrate liver,
and is a non-competitive inhibitor with respect to all substrates [119]. Chlorothricin not only protects chicken liver
PC against cold inactivation, but also protects rat liver PC
against inactivation by trinitrobenzenesulfonate at the allosteric activator site, though in neither case does it confer the
same degree of protection as does acetyl CoA [119, 121].
Despite these findings, Schindler and Scrutton [119] argue
against chlorothricin binding in the allosteric activator binding site of vertebrate PC on the basis of its non-competitive
inhibition of acetyl CoA activation and its lack of sensitivity
to inhibition of rat liver PC that has an inactivated allosteric
activator binding site. While there are no other reports of PC
inhibition by other macrolide-type antibiotics, NMR studies
probing the inhibitory effects of the polyene antibiotic, amphotericin B, on glucose metabolism in S. cerevisiae suggest
that it may function by reducing PC activity [122].
Benzoate
Griffith et al. first demonstrated that PC activity is inhibited by sodium benzoate in the intact mitochondria of rat
liver [123]. Even though benzoate is converted to benzoyl
CoA in the rat liver [113, 123, 124] benzoyl CoA does not
directly compete with acetyl CoA activation in PC from mitochondrial extracts [123, 124]. Rather, benzoate exerts its
inhibitory effect on PC through its conversion to benzoyl
CoA and subsequent depletion of the pool of available coenzyme A and acetyl CoA [123]. The addition of 1 mM sodium
benzoate resulted in the reduction of intracellular acetyl CoA
concentration from 0.5 mM (a concentration greater than Ka
) to 0.1 mM (a concentration less than K a) [113] .
Phenylacetate/Phenylacetyl CoA
Bahl et al. [125] first reported the suppression of liver
gluconeogenesis by the inhibition of PC using phenylacetic
acid. HPLC analysis of rat liver mitochondrial preparations
demonstrated that phenylacetate was largely converted to
phenylacetyl CoA in vivo. Kinetic investigations of the purified rat liver PC demonstrated that, at high acetyl CoA concentrations (> 100 μM) phenylacetyl CoA inhibits PC while
the precursor phenylacetate has no inhibitory effect on the
enzyme activity. At low acetyl CoA concentrations, phenylacetyl CoA inhibited the enzyme in the 5 to 50 μM range.
The report of phenylacetyl CoA inhibition by Bahl et al.
conflicts with earlier reports that both phenylacetyl CoA and
benzoyl CoA are weak activators of PC from rat liver and
thermophilic Bacillus [93, 110]. It is possible, therefore, that
the mechanism of inhibition also includes the sequestration
of mitochondrial CoA pools, similar to the proposed mode of
benzoate inhibition. Phenylacetate has been used as an effective inhibitor to study the role of PC in GSIS in INS-1 cells
[126, 127] and in the isolated pancreatic islets of rats [8,
127].
Acyl CoA Analogues
Several studies have revealed that a broad spectrum of
acyl CoA analogues and acetyl CoA fragments will maintain
low levels of allosteric activation for PC isolated from a variety of microbial and vertebrate species, indicating that the
allosteric site of the enzyme is relatively tolerant to modifications of acetyl CoA [21, 36, 93, 110, 128]. In chicken liver
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PC, acyl CoA analogues that have acyl chain lengths less
than 4 act as allosteric activators while the longer chain acyl
CoA analogues act as allosteric, competitive inhibitors with
respect to acetyl CoA. Increasing the acyl chain lengths from
4 (valeryl CoA) to 10 (n-decanoyl CoA), resulted in increases in both the IC50 and Hill coefficients [110]. Contrary
to chicken liver PC, acyl CoA analogues of any length are
activators of the rat liver and Bacillus PC enzymes [36, 93].
Carboxylated acyl analogues of acetyl CoA are competitive
inhibitors of rat liver PC, chicken liver PC and Bacillus PC
with respect to acetyl CoA. Of the carboxylated analogues
examined, methylmalonyl CoA exhibits the highest degree
of inhibition against both chicken liver and rat liver PC [36,
110]. Furthermore, rat liver PC is also inhibited by succinyl
CoA, maleyl CoA and glutaryl CoA [110].
Analogues of the diphosphoadenosine portion of acetyl
CoA do not activate PC and, in fact, will act as competitive
inhibitors with respect to acetyl CoA in PC from both rat and
chicken liver PC [36, 110]. Unlike other acyl CoA analogues, acetoacetyl CoA is a noncompetitive inhibitor of
chicken liver PC with respect to all substrates. Surprisingly,
acetoacetyl CoA is also a noncompetitive inhibtor with respect to acetyl-CoA and, furthermore, the inhibition results
in a decreased Hill coefficient for acetyl CoA activation in
chicken liver PC [115, 129]. While acetoacetyl CoA is a
much weaker inhibitor for rat liver PC and has no effect on
the acetyl CoA Hill coefficient in rat liver PC [115] these
data, nevertheless, suggest that acetoacetyl CoA binds at a
unique allosteric site, though the physiological relevance of
this effect is unclear [115].

The Open Enzyme Inhibition Journal, 2010, Volume 3

light of the structure-function relationships that are currently
being investigated. Since PC has been shown to be a major
bottleneck in the commercial production of amino acids, the
development of small molecule effectors, which regulate
enzymatic activity, may also be of importance in various
industrial applications. [134]. Moreover, with the vast
amount of available evidence correlating PC activity and
the development of debilitating metabolic diseases, such as
Type II diabetes, these initial inhibitor studies may provide
valuable starting points for the design of drugs that modulate
the activity of the enzyme for therapeutic purposes.
ABBREVIATIONS
PC

=

Pyruvate carboxylase

BC

=

Biotin carboxylase

CT

=

Carboxyl transferase

BCCP

=

Biotin-carboxyl carrier protein

Acetyl
=
Coenzyme A

CONCLUDING REMARKS
Much of the research focusing on the inhibition of pyruvate carboxylase that has been undertaken over the last forty
or so years has greatly facilitated a preliminary understanding of the overall PC mechanism. With the recent solution of
several structures of the enzyme, the results of these inhibition studies can now be fully realized and re-evaluated in

Acetyl CoA
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